BioSpace News Archive

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Akumin Inc., a leading provider of outpatient diagnostic imaging services in the U.S., today announced a strategic collaboration to deploy Philips’ new Radiology Operations Command Center across Akumin’s outpatient imaging centers and co-create clinical standards for Akumin’s MR and CT imaging modalities.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it has completed the acquisition of ACEA Therapeutics Inc. (“ACEA”).

INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the United States Adopted Name Council (USAN) has adopted the name “Pegipanermin” for its lead clinical candidate, XPro1595.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC; NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today the formation of a six member advisory board of leading neurosurgeons

Aetna Better Health of Nevada1, the Medicaid managed care business of Aetna®, a CVS Health® company, announced it has donated $65,000 to R.E.A.C.H., a non-profit organization that works to improve community health services and access to care in Nevada.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its wholly-owned subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has secured a safeCircle™ pooled COVID-19 surveillance testing contract with Camp Chateaugay , an overnight summer camp program for teens and kids based in New York’s Adirondack Mountain region

Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer

As part of the 2021 ASCO Annual Meeting, precision oncology company Lucence is sharing real-world data supporting clinical applications of its amplicon-based liquid biopsy assay.

PRESS RELEASE AB SCIENCE WILL HOST A LIVE WEBCAST ON THURSDAY JUNE 3, 2021 FOLLOWING THE VOLUNTARY HOLD IN THE CLINICAL STUDIES OF MASITINIB

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced the enrollment of the first patient in a Phase 1b clinical trial with City of Hope, a world-renowned independent cancer research and treatment center.